nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SCN5A—Riluzole—amyotrophic lateral sclerosis	0.621	0.812	CbGbCtD
Lidocaine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.144	0.188	CbGbCtD
Lidocaine—SCN3A—spinal nerve—amyotrophic lateral sclerosis	0.0154	0.282	CbGeAlD
Lidocaine—Hypoaesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0718	CcSEcCtD
Lidocaine—Methaemoglobinaemia—Riluzole—amyotrophic lateral sclerosis	0.00984	0.0637	CcSEcCtD
Lidocaine—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.00887	0.0575	CcSEcCtD
Lidocaine—Hyperacusis—Riluzole—amyotrophic lateral sclerosis	0.00776	0.0503	CcSEcCtD
Lidocaine—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00705	0.0457	CcSEcCtD
Lidocaine—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00617	0.04	CcSEcCtD
Lidocaine—SCN10A—peripheral nervous system—amyotrophic lateral sclerosis	0.00419	0.0763	CbGeAlD
Lidocaine—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00384	0.0249	CcSEcCtD
Lidocaine—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00384	0.0249	CcSEcCtD
Lidocaine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00378	0.0245	CcSEcCtD
Lidocaine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00352	0.0228	CcSEcCtD
Lidocaine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00341	0.0221	CcSEcCtD
Lidocaine—SCN10A—nerve—amyotrophic lateral sclerosis	0.00326	0.0595	CbGeAlD
Lidocaine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00306	0.0198	CcSEcCtD
Lidocaine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0187	CcSEcCtD
Lidocaine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0185	CcSEcCtD
Lidocaine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0181	CcSEcCtD
Lidocaine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0181	CcSEcCtD
Lidocaine—Coma—Riluzole—amyotrophic lateral sclerosis	0.00264	0.0171	CcSEcCtD
Lidocaine—SCN2A—hindbrain—amyotrophic lateral sclerosis	0.00253	0.0462	CbGeAlD
Lidocaine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00249	0.0161	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00217	0.0141	CcSEcCtD
Lidocaine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0136	CcSEcCtD
Lidocaine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0136	CcSEcCtD
Lidocaine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0133	CcSEcCtD
Lidocaine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.002	0.0129	CcSEcCtD
Lidocaine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.002	0.0129	CcSEcCtD
Lidocaine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0118	CcSEcCtD
Lidocaine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0118	CcSEcCtD
Lidocaine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0103	CcSEcCtD
Lidocaine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0102	CcSEcCtD
Lidocaine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00958	CcSEcCtD
Lidocaine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00946	CcSEcCtD
Lidocaine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00943	CcSEcCtD
Lidocaine—SCN2A—brainstem—amyotrophic lateral sclerosis	0.00145	0.0265	CbGeAlD
Lidocaine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00941	CcSEcCtD
Lidocaine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00936	CcSEcCtD
Lidocaine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00879	CcSEcCtD
Lidocaine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00873	CcSEcCtD
Lidocaine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00854	CcSEcCtD
Lidocaine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0085	CcSEcCtD
Lidocaine—Chills—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00844	CcSEcCtD
Lidocaine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00804	CcSEcCtD
Lidocaine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00802	CcSEcCtD
Lidocaine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00795	CcSEcCtD
Lidocaine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00792	CcSEcCtD
Lidocaine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00767	CcSEcCtD
Lidocaine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00753	CcSEcCtD
Lidocaine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00748	CcSEcCtD
Lidocaine—SCN9A—spinal cord—amyotrophic lateral sclerosis	0.00114	0.0209	CbGeAlD
Lidocaine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0072	CcSEcCtD
Lidocaine—EGFR—cerebellum—amyotrophic lateral sclerosis	0.0011	0.0201	CbGeAlD
Lidocaine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0071	CcSEcCtD
Lidocaine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00707	CcSEcCtD
Lidocaine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00697	CcSEcCtD
Lidocaine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00695	CcSEcCtD
Lidocaine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00674	CcSEcCtD
Lidocaine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00668	CcSEcCtD
Lidocaine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00668	CcSEcCtD
Lidocaine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00658	CcSEcCtD
Lidocaine—SCN2A—medulla oblongata—amyotrophic lateral sclerosis	0.00101	0.0185	CbGeAlD
Lidocaine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00656	CcSEcCtD
Lidocaine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000998	0.00646	CcSEcCtD
Lidocaine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000964	0.00625	CcSEcCtD
Lidocaine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000927	0.006	CcSEcCtD
Lidocaine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00596	CcSEcCtD
Lidocaine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000917	0.00594	CcSEcCtD
Lidocaine—SCN2A—spinal cord—amyotrophic lateral sclerosis	0.000903	0.0165	CbGeAlD
Lidocaine—EGFR—brain—amyotrophic lateral sclerosis	0.000895	0.0163	CbGeAlD
Lidocaine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000891	0.00577	CcSEcCtD
Lidocaine—SCN3A—medulla oblongata—amyotrophic lateral sclerosis	0.00089	0.0162	CbGeAlD
Lidocaine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00572	CcSEcCtD
Lidocaine—SCN10A—spinal cord—amyotrophic lateral sclerosis	0.000871	0.0159	CbGeAlD
Lidocaine—SCN4A—nervous system—amyotrophic lateral sclerosis	0.00086	0.0157	CbGeAlD
Lidocaine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00551	CcSEcCtD
Lidocaine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000833	0.0152	CbGeAlD
Lidocaine—SCN4A—central nervous system—amyotrophic lateral sclerosis	0.000828	0.0151	CbGeAlD
Lidocaine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00082	0.00531	CcSEcCtD
Lidocaine—SCN3A—spinal cord—amyotrophic lateral sclerosis	0.000794	0.0145	CbGeAlD
Lidocaine—SCN2A—nervous system—amyotrophic lateral sclerosis	0.000761	0.0139	CbGeAlD
Lidocaine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00492	CcSEcCtD
Lidocaine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00074	0.0048	CcSEcCtD
Lidocaine—SCN9A—brain—amyotrophic lateral sclerosis	0.000737	0.0134	CbGeAlD
Lidocaine—SCN10A—nervous system—amyotrophic lateral sclerosis	0.000734	0.0134	CbGeAlD
Lidocaine—SCN2A—central nervous system—amyotrophic lateral sclerosis	0.000733	0.0134	CbGeAlD
Lidocaine—SCN2A—cerebellum—amyotrophic lateral sclerosis	0.000716	0.0131	CbGeAlD
Lidocaine—SCN10A—central nervous system—amyotrophic lateral sclerosis	0.000707	0.0129	CbGeAlD
Lidocaine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000682	0.00442	CcSEcCtD
Lidocaine—SCN3A—nervous system—amyotrophic lateral sclerosis	0.000669	0.0122	CbGeAlD
Lidocaine—SCN5A—nervous system—amyotrophic lateral sclerosis	0.000667	0.0122	CbGeAlD
Lidocaine—SCN4A—brain—amyotrophic lateral sclerosis	0.000657	0.012	CbGeAlD
Lidocaine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000656	0.00425	CcSEcCtD
Lidocaine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000651	0.00421	CcSEcCtD
Lidocaine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00065	0.00421	CcSEcCtD
Lidocaine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000646	0.00419	CcSEcCtD
Lidocaine—SCN3A—central nervous system—amyotrophic lateral sclerosis	0.000644	0.0117	CbGeAlD
Lidocaine—SCN5A—central nervous system—amyotrophic lateral sclerosis	0.000642	0.0117	CbGeAlD
Lidocaine—SCN3A—cerebellum—amyotrophic lateral sclerosis	0.00063	0.0115	CbGeAlD
Lidocaine—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.000629	0.0115	CbGeAlD
Lidocaine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000613	0.00397	CcSEcCtD
Lidocaine—SCN2A—brain—amyotrophic lateral sclerosis	0.000582	0.0106	CbGeAlD
Lidocaine—SCN10A—brain—amyotrophic lateral sclerosis	0.000561	0.0102	CbGeAlD
Lidocaine—SLC22A5—medulla oblongata—amyotrophic lateral sclerosis	0.000516	0.00941	CbGeAlD
Lidocaine—SCN3A—brain—amyotrophic lateral sclerosis	0.000511	0.00932	CbGeAlD
Lidocaine—CYP2A6—brain—amyotrophic lateral sclerosis	0.000511	0.00932	CbGeAlD
Lidocaine—SCN5A—brain—amyotrophic lateral sclerosis	0.00051	0.0093	CbGeAlD
Lidocaine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000477	0.00871	CbGeAlD
Lidocaine—SLC22A5—spinal cord—amyotrophic lateral sclerosis	0.00046	0.00839	CbGeAlD
Lidocaine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000375	0.00683	CbGeAlD
Lidocaine—SLC22A5—cerebellum—amyotrophic lateral sclerosis	0.000365	0.00665	CbGeAlD
Lidocaine—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000337	0.00614	CbGeAlD
Lidocaine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000324	0.00591	CbGeAlD
Lidocaine—SLC22A5—brain—amyotrophic lateral sclerosis	0.000296	0.0054	CbGeAlD
Lidocaine—CYP2C8—brain—amyotrophic lateral sclerosis	0.000287	0.00523	CbGeAlD
Lidocaine—CYP2B6—brain—amyotrophic lateral sclerosis	0.000257	0.00469	CbGeAlD
Lidocaine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000254	0.00464	CbGeAlD
Lidocaine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00025	0.00456	CbGeAlD
Lidocaine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000245	0.00446	CbGeAlD
Lidocaine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000241	0.00439	CbGeAlD
Lidocaine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000239	0.00437	CbGeAlD
Lidocaine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000235	0.00429	CbGeAlD
Lidocaine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000214	0.00389	CbGeAlD
Lidocaine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000191	0.00349	CbGeAlD
Lidocaine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00018	0.00328	CbGeAlD
Lidocaine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000173	0.00316	CbGeAlD
Lidocaine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000169	0.00309	CbGeAlD
Lidocaine—ABCB1—brain—amyotrophic lateral sclerosis	0.000138	0.00251	CbGeAlD
Lidocaine—CYP3A7—Metabolism—FIG4—amyotrophic lateral sclerosis	3.33e-05	0.00125	CbGpPWpGaD
Lidocaine—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	3.3e-05	0.00124	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	3.28e-05	0.00123	CbGpPWpGaD
Lidocaine—EGFR—Disease—CHMP2B—amyotrophic lateral sclerosis	3.26e-05	0.00122	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	3.26e-05	0.00122	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.26e-05	0.00122	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.26e-05	0.00122	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.25e-05	0.00122	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.21e-05	0.0012	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—GSR—amyotrophic lateral sclerosis	3.17e-05	0.00119	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.14e-05	0.00118	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.14e-05	0.00118	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	3.13e-05	0.00117	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	3.12e-05	0.00117	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.08e-05	0.00116	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.08e-05	0.00116	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.05e-05	0.00114	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—DAO—amyotrophic lateral sclerosis	3.01e-05	0.00113	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	3.01e-05	0.00113	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	3.01e-05	0.00113	CbGpPWpGaD
Lidocaine—EGFR—Disease—PLB1—amyotrophic lateral sclerosis	2.95e-05	0.0011	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	2.88e-05	0.00108	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	2.82e-05	0.00106	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.82e-05	0.00106	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.8e-05	0.00105	CbGpPWpGaD
Lidocaine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.8e-05	0.00105	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	2.78e-05	0.00104	CbGpPWpGaD
Lidocaine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.77e-05	0.00104	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	2.76e-05	0.00103	CbGpPWpGaD
Lidocaine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.76e-05	0.00103	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	2.76e-05	0.00103	CbGpPWpGaD
Lidocaine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.73e-05	0.00102	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.69e-05	0.00101	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—ATF1—amyotrophic lateral sclerosis	2.68e-05	0.001	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.66e-05	0.000998	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	2.66e-05	0.000996	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	2.65e-05	0.000992	CbGpPWpGaD
Lidocaine—EGFR—Disease—VCP—amyotrophic lateral sclerosis	2.63e-05	0.000984	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	2.63e-05	0.000984	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.62e-05	0.000982	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.61e-05	0.000979	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	2.61e-05	0.000978	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	2.61e-05	0.000978	CbGpPWpGaD
Lidocaine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	2.61e-05	0.000976	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CHAT—amyotrophic lateral sclerosis	2.6e-05	0.000976	CbGpPWpGaD
Lidocaine—EGFR—Immune System—DCTN1—amyotrophic lateral sclerosis	2.6e-05	0.000975	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.6e-05	0.000974	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.59e-05	0.00097	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.59e-05	0.00097	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.56e-05	0.00096	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CASP9—amyotrophic lateral sclerosis	2.55e-05	0.000955	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.53e-05	0.000948	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	2.51e-05	0.000939	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.5e-05	0.000935	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.46e-05	0.000923	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.46e-05	0.000921	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	2.45e-05	0.000918	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	2.45e-05	0.000917	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.43e-05	0.000912	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.42e-05	0.000906	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	2.41e-05	0.000903	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	2.39e-05	0.000894	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	2.37e-05	0.000888	CbGpPWpGaD
Lidocaine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.37e-05	0.000888	CbGpPWpGaD
Lidocaine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.34e-05	0.000875	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.32e-05	0.000871	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.32e-05	0.000871	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	2.28e-05	0.000856	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.27e-05	0.000852	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.27e-05	0.000852	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	2.26e-05	0.000845	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.24e-05	0.00084	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.23e-05	0.000837	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	2.23e-05	0.000835	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.22e-05	0.000831	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	2.22e-05	0.00083	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.21e-05	0.000827	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.21e-05	0.000827	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	2.18e-05	0.000818	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	2.18e-05	0.000816	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	2.14e-05	0.000803	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	2.14e-05	0.000803	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	2.14e-05	0.000801	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	2.12e-05	0.000796	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	2.12e-05	0.000796	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	2.11e-05	0.00079	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	2.1e-05	0.000785	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.09e-05	0.000784	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	2.09e-05	0.000782	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.08e-05	0.000779	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.06e-05	0.000773	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.02e-05	0.000755	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.02e-05	0.000755	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.01e-05	0.000754	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.98e-05	0.000742	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	1.97e-05	0.000738	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.96e-05	0.000734	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	1.94e-05	0.000728	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.94e-05	0.000727	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.93e-05	0.000724	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	1.93e-05	0.000724	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	1.89e-05	0.000707	CbGpPWpGaD
Lidocaine—EGFR—Disease—CST3—amyotrophic lateral sclerosis	1.89e-05	0.000706	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	1.88e-05	0.000705	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	1.85e-05	0.000692	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.84e-05	0.000689	CbGpPWpGaD
Lidocaine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.83e-05	0.000685	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.82e-05	0.000683	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.82e-05	0.000681	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.82e-05	0.00068	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.82e-05	0.00068	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—C3—amyotrophic lateral sclerosis	1.81e-05	0.000679	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.81e-05	0.000677	CbGpPWpGaD
Lidocaine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.8e-05	0.000676	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.8e-05	0.000673	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.78e-05	0.000668	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.75e-05	0.000657	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	1.74e-05	0.000652	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	1.73e-05	0.000649	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.71e-05	0.000642	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.7e-05	0.000639	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	1.7e-05	0.000636	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.69e-05	0.000634	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.69e-05	0.000633	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.67e-05	0.000625	CbGpPWpGaD
Lidocaine—EGFR—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.66e-05	0.000623	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.66e-05	0.000622	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	1.65e-05	0.000619	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.64e-05	0.000616	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MMP9—amyotrophic lateral sclerosis	1.61e-05	0.000603	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.59e-05	0.000594	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.58e-05	0.000593	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.58e-05	0.00059	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.56e-05	0.000586	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ATF1—amyotrophic lateral sclerosis	1.56e-05	0.000584	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	1.56e-05	0.000584	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.55e-05	0.00058	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.54e-05	0.000578	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	1.54e-05	0.000575	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	1.52e-05	0.000571	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CASP9—amyotrophic lateral sclerosis	1.48e-05	0.000556	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	1.45e-05	0.000544	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.45e-05	0.000542	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	1.43e-05	0.000536	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.41e-05	0.00053	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.4e-05	0.000525	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.4e-05	0.000525	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.4e-05	0.000524	CbGpPWpGaD
Lidocaine—EGFR—Disease—CASP9—amyotrophic lateral sclerosis	1.37e-05	0.000514	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	1.32e-05	0.000494	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.31e-05	0.000492	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.31e-05	0.000492	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	0.00049	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.29e-05	0.000482	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.28e-05	0.00048	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.28e-05	0.00048	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ERBB4—amyotrophic lateral sclerosis	1.27e-05	0.000476	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.25e-05	0.000469	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.25e-05	0.000467	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	0.00045	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD40LG—amyotrophic lateral sclerosis	1.19e-05	0.000448	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.19e-05	0.000446	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.17e-05	0.00044	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.17e-05	0.00044	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.16e-05	0.000436	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.16e-05	0.000433	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.15e-05	0.000431	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.15e-05	0.00043	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.12e-05	0.00042	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.11e-05	0.000417	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.08e-05	0.000406	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.08e-05	0.000406	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.07e-05	0.000403	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.07e-05	0.000402	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-05	0.000396	CbGpPWpGaD
Lidocaine—EGFR—Immune System—C3—amyotrophic lateral sclerosis	1.06e-05	0.000396	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.03e-05	0.000386	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.01e-05	0.000379	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.01e-05	0.000378	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	9.95e-06	0.000373	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	9.89e-06	0.000371	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.78e-06	0.000366	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.6e-06	0.00036	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	9.44e-06	0.000354	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.3e-06	0.000349	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	9.18e-06	0.000344	CbGpPWpGaD
Lidocaine—EGFR—Disease—APOE—amyotrophic lateral sclerosis	9.08e-06	0.00034	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	8.9e-06	0.000333	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	8.82e-06	0.00033	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.55e-06	0.00032	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.53e-06	0.000319	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	8.41e-06	0.000315	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.36e-06	0.000313	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.22e-06	0.000308	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.05e-06	0.000302	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.84e-06	0.000294	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.73e-06	0.000289	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	7.68e-06	0.000288	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	7.54e-06	0.000282	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.25e-06	0.000272	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	7.08e-06	0.000265	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	7.03e-06	0.000264	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.88e-06	0.000258	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.88e-06	0.000258	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.83e-06	0.000256	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.78e-06	0.000254	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.73e-06	0.000252	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	6.45e-06	0.000242	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.36e-06	0.000238	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.32e-06	0.000237	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—amyotrophic lateral sclerosis	6.22e-06	0.000233	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.18e-06	0.000232	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.82e-06	0.000218	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	5.82e-06	0.000218	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.51e-06	0.000207	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.35e-06	0.000201	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.25e-06	0.000197	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	5.2e-06	0.000195	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	5.08e-06	0.000191	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.07e-06	0.00019	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.82e-06	0.000181	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.78e-06	0.000179	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.74e-06	0.000178	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.71e-06	0.000177	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.66e-06	0.000175	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.42e-06	0.000166	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	4.4e-06	0.000165	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.39e-06	0.000165	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.36e-06	0.000163	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.05e-06	0.000152	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.04e-06	0.000151	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.84e-06	0.000144	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.82e-06	0.000143	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.72e-06	0.000139	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	3.62e-06	0.000135	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	3.58e-06	0.000134	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.56e-06	0.000134	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.48e-06	0.000131	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.43e-06	0.000129	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.13e-06	0.000117	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	3.06e-06	0.000115	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.02e-06	0.000113	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.87e-06	0.000108	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.63e-06	9.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.59e-06	9.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.48e-06	9.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.46e-06	9.2e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.36e-06	8.86e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.1e-06	7.86e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.62e-06	6.07e-05	CbGpPWpGaD
